302 related articles for article (PubMed ID: 36831449)
21. Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management.
Plunkett KR; Armitage JD; Inderjeeth AJ; McDonnell AM; Waithman J; Lau PKH
Front Immunol; 2022; 13():1048758. PubMed ID: 36466880
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapy of Melanoma.
Tarhini AA
Curr Mol Pharmacol; 2016; 9(3):196-207. PubMed ID: 26177647
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?
Ziogas DC; Theocharopoulos C; Koutouratsas T; Haanen J; Gogas H
Cancer Treat Rev; 2023 Feb; 113():102499. PubMed ID: 36542945
[TBL] [Abstract][Full Text] [Related]
24. The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With Immunotherapy.
Puza CJ; Bressler ES; Terando AM; Howard JH; Brown MC; Hanks B; Salama AKS; Beasley GM
J Surg Res; 2019 Apr; 236():209-215. PubMed ID: 30694757
[TBL] [Abstract][Full Text] [Related]
25. Intralesional and systemic immunotherapy for metastatic melanoma.
Luu C; Khushalani NI; Zager JS
Expert Opin Biol Ther; 2016 Dec; 16(12):1491-1499. PubMed ID: 27602429
[TBL] [Abstract][Full Text] [Related]
26. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.
Pennock GK; Chow LQ
Oncologist; 2015 Jul; 20(7):812-22. PubMed ID: 26069281
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy in Melanoma: Highlights for the General Practitioner.
Ben Aïssa A
Praxis (Bern 1994); 2023; 112(3):135-142. PubMed ID: 36855885
[No Abstract] [Full Text] [Related]
28. Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitor-refractory, advanced-stage melanoma.
Seremet T; Planken S; Schwarze JK; Jansen Y; Vandeweerd L; van den Begin R; Tsechelidis I; Lienard D; Del Marmol V; Neyns B
Melanoma Res; 2019 Feb; 29(1):85-88. PubMed ID: 30211812
[TBL] [Abstract][Full Text] [Related]
29. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Vijayakumar G; McCroskery S; Palese P
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
[TBL] [Abstract][Full Text] [Related]
30. Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.
Luo C; Wang P; He S; Zhu J; Shi Y; Wang J
Front Oncol; 2022; 12():919072. PubMed ID: 35795050
[TBL] [Abstract][Full Text] [Related]
31. The next generation of immunotherapy: keeping lung cancer in check.
Somasundaram A; Burns TF
J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
[TBL] [Abstract][Full Text] [Related]
32. Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma.
Cavalcante L; Chowdhary A; Sosman JA; Chandra S
Am J Clin Dermatol; 2018 Oct; 19(5):657-670. PubMed ID: 29961183
[TBL] [Abstract][Full Text] [Related]
33. The treatment of advanced melanoma: a review of systemic and local therapies in combination with immune checkpoint inhibitors in phase 1 and 2 clinical trials.
DePalo DK; Tarhini A; Zager JS
Expert Opin Investig Drugs; 2022 Jan; 31(1):95-104. PubMed ID: 34996314
[TBL] [Abstract][Full Text] [Related]
34. The Era of Checkpoint Inhibition: Lessons Learned from Melanoma.
Paschen A; Schadendorf D
Recent Results Cancer Res; 2020; 214():169-187. PubMed ID: 31473853
[TBL] [Abstract][Full Text] [Related]
35. MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation.
Bommareddy PK; Aspromonte S; Zloza A; Rabkin SD; Kaufman HL
Sci Transl Med; 2018 Dec; 10(471):. PubMed ID: 30541787
[TBL] [Abstract][Full Text] [Related]
36. cGAS-STING, an important pathway in cancer immunotherapy.
Jiang M; Chen P; Wang L; Li W; Chen B; Liu Y; Wang H; Zhao S; Ye L; He Y; Zhou C
J Hematol Oncol; 2020 Jun; 13(1):81. PubMed ID: 32571374
[TBL] [Abstract][Full Text] [Related]
37. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy).
Ascierto PA; Agarwala SS; Blank C; Caracò C; Carvajal RD; Ernstoff MS; Ferrone S; Fox BA; Gajewski TF; Garbe C; Grob JJ; Hamid O; Krogsgaard M; Lo RS; Lund AW; Madonna G; Michielin O; Neyns B; Osman I; Peters S; Poulikakos PI; Quezada SA; Reinfeld B; Zitvogel L; Puzanov I; Thurin M
J Transl Med; 2022 Sep; 20(1):391. PubMed ID: 36058945
[TBL] [Abstract][Full Text] [Related]
38. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
39. Emerging Strategies in Systemic Therapy for the Treatment of Melanoma.
Ascierto PA; Flaherty K; Goff S
Am Soc Clin Oncol Educ Book; 2018 May; 38():751-758. PubMed ID: 30231371
[TBL] [Abstract][Full Text] [Related]
40. Current knowledge about immunotherapy resistance for melanoma and potential predictive and prognostic biomarkers.
Song L; Yang Y; Tian X
Cancer Drug Resist; 2024; 7():17. PubMed ID: 38835341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]